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Abstract
Background: Human β-defensins (hBDs) are antimicrobial peptides with a role in innate immune defense. Our
laboratory previously showed that a single nucleotide polymorphism (SNP) in the 5' untranslated region of the
hBD1 gene (DEFB1), denoted -44 (rs1800972), is correlated with protection from oral Candida. Because this SNP
alters the putative mRNA structure, we hypothesized that it alters hBD1 expression.
Methods: Transfection of reporter constructs and evaluation of antimicrobial activity and mRNA expression
levels in keratinocytes from multiple donors were used to evaluate the effect of this SNP on constitutive and
induced levels of expression.
Results: Transfection of CAT reporter constructs containing the 5' untranslated region showed that the -44 G
allele yielded a 2-fold increase in CAT protein compared to other common haplotypes suggesting a cis effect on
transcription or translation. The constitutive hBD1 mRNA level in human oral keratinocytes was significantly
greater in cells from donors with the -44 GG genotype compared to those with the common CC genotype.
Surprisingly, the hBD3 mRNA level as well as antimicrobial activity of keratinocyte extracts also correlated with
the -44 G allele. Induced levels of hBD1, hBD2, and hBD3 mRNA were evaluated in keratinocytes challenged with
Toll-like receptor 2 and 4 ligands, interleukin-1β, TNFα, and interferon-γ (IFNγ). In contrast to constitutive
expression levels, IFNγ-induced keratinocyte hBD1 and hBD3 mRNA expression was significantly greater in cells
with the common CC genotype, but there was no clear correlation of genotype with hBD2 expression.
Conclusion: The DEFB1 -44 G allele is associated with an increase in overall constitutive antimicrobial activity
and expression of hBD1 and hBD3 in a manner that is consistent with protection from candidiasis, while the more
common C allele is associated with IFNγ inducibility of these β-defensins and is likely to be more protective in
conditions that enhance IFNγ expression such as chronic periodontitis. These results suggest a complex
relationship between genetics and defensin expression that may influence periodontal health and innate immune
responses.
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Background
The health of mucosal surfaces, the oral cavity, and skin is
maintained by a complex balance among commensal and
pathogenic organisms and host defenses [1-4]. Epithelial
cells express multiple antimicrobial peptides that act as a
first line of defense and help to keep these microbes in
balance (reviewed by Dale and Fredericks [5]). In addition
to functioning as antimicrobial agents, these peptides
have immunomodulatory properties and serve as links
between the innate and acquired immune systems. For
example, the β-defensins act as chemokines and signaling
molecules to antigen presenting cells [6,7] and thus func-
tion more broadly in host defense as initiators of the
acquired immune system.
Over 30 human β-defensins genes have been identified
[8], however most studies have focused on hBD1, -2, and
-3, which are expressed in the oral cavity [9-14], skin [15],
gut and other epithelia [16-18]. HBD2 and hBD3 are
induced by various bacterial components and cytokines,
while hBD1 is constitutively expressed [5]. Nevertheless,
the level of hBD1 expression varies among individuals
and it has been suggested that this variation is due to
genetic differences in the DEFB1  gene encoding hBD1
[12,13,19]. This type of individual variation is important
in the functional diversity that underlies the regulation of
innate immune function and is evident in many compo-
nents of innate immunity [20].
Growing evidence links antimicrobial peptides with
resistance or susceptibility to mucosal infections and dis-
ease susceptibility [18,21-23]. For example, levels of
hBD2 and LL-37 are low in individuals with atopic derma-
titis [24] and LL-37 and α-defensins are poorly expressed
in a severe genetic form of periodontal disease [25]. Two
types of genetic polymorphisms have been identified in
the genes encoding defensins, copy number polymor-
phisms (CNPs) and single nucleotide polymorphisms
(SNPs). Copy number polymorphism in the α-defensin
gene cluster is associated with expression level in neu-
trophils [26,27]. Low expression of both α – and β-
defensins are associated with specific forms of Crohn's
disease and low β-defensin copy number increases suscep-
tibility to colonic Crohn's disease [28,29]. Multiple SNPs
within the DEFB1 gene [30-33] have also been associated
with health risks. Previous work in our laboratory showed
that a C → G SNP in the DEFB1 5' untranslated region
(UTR) at position -44 relative to the AUG protein initia-
tion site (SNP rs1800972) is correlated with low oral lev-
els of the common yeast, Candida albicans [34]. This SNP
is also associated with protection from chronic obstructive
pulmonary disease [35] and vertical transmission of HIV
infection [36-38], as well as Crohn's disease [39]. In the
skin this SNP is associated with atopic dermatitis [40]
while high copy number in the β-defensin gene cluster
increases the risk for psoriasis [41].
The objective of this study was to examine the association
of the DEFB1 -44 SNP and expression of hBD1 in oral
keratinocytes. We used two independent methods to eval-
uate the effect of this SNP on constitutive levels of protein
and/or mRNA expression as well as the antimicrobial
activity of epithelial cell extracts. We also evaluated the
association of this SNP with expression of constitutive
and induced levels of hBD2 and hBD3 which are encoded
by genes located in a cluster near the DEFB1 gene on chro-
mosome 8p22–23 [42]. Our results show that the -44 SNP
is associated with increased expression of hBD1 and hBD3
and that the DEFB1  -44 SNP has a complex effect on
expression and inducibility of multiple β-defensins.
Methods
Human oral keratinocytes (HOKs)
Human oral keratinocytes (HOKs) were prepared from
multiple individual donors in accordance with an
approved University of Washington Institutional Review
Board protocol. Oral cells were obtained and cultured as
previously described [12]. Briefly, primary epithelial cells
from gingival tissue were grown in keratinocyte basal
medium (KBM, Cambrex Bioscience, Walkersville, MD)
with keratinocyte growth medium (KGM) supplements in
0.03 mM Ca2+ for three passages, then raised to either 0.15
mM or 0.6 mM Ca2+ to induce differentiation. Cells were
harvested for DNA or RNA after growth for an additional
48 hr and harvested for protein after 96 hr as described
below. For induced cultures cells at 80% confluence were
stimulated with 100 ng/ml final concentration of
Eschericia coli lipopolysaccharide (LPS) (Sigma, St. Louis,
MO), PAM3CSK4 (Invitrogen, San Diego, CA),
interleukin1β (IL1β, Cell Sciences, Canton, MA), TNFα
(Cell Sciences), and interferon-γ (IFNγ, Cell Sciences) for
18 hr in 0.15 mM Ca+2 then harvested for RNA, The E. coli
serotype 0127:B8 LPS was further purified by phenol
extraction as previously described [43].
Genotyping
Genomic DNA was extracted from HOKs (DNeasy tissue
kit, Qiagen, Valencia, CA), and the concentration meas-
ured by Nanodrop absorbance (ThermoScientific, Wilm-
ington, DE). The hBD1 5' UTR was sequenced in the Dept.
of Genome Sciences, University of Washington, courtesy
of Dr. Robert Livingston or by Polymorphic DNA Tech-
nologies Inc (Alameda, CA) using primers specific for
exon 1 (Table 1).
Putative RNA folding
The hBD1 mRNA folding characteristics were estimated
using the MFOLD program (Rensselaer Polytechnic Insti-
tute, Troy, NY) [44].BMC Oral Health 2009, 9:21 http://www.biomedcentral.com/1472-6831/9/21
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Plasmid constructs
We prepared four constructs containing the most com-
mon haplotypes of the three known hBD1 5' UTR SNPs (-
20, -44, -52) [31] (GenBank accession no. U50930; rs
11362, 1800972, 1799946) upstream of the chloram-
phenicol acetyltransferase (CAT) reporter gene using the
pc DNA3CAT plasmid (Invitrogen, Carlesbad, CA). For
details of plasmid construction see Additional file 1. A
construct with the CMV 5' UTR and a promoterless pGEM-
NCMV were created and served as controls. pKTCAT is a
promoterless CAT reporter plasmid that contains the
BamHI-Hind III CAT fragment of pSV0 CAT cloned into
the AatII-Hind III sites of pUCl8 [45]. pcDNA3CAT is a
positive control CAT plasmid. The constructs with the
common haplotypes were: pGEM-ACG (-20 = A, -44 = C,
-52 = G), pGEM-GCA and pGEM-GGG; an additional con-
struct, pGEM-GCG, was also prepared as a direct control
for pGEM-GGG, even though this haplotype has not been
observed in the general population [31].
Cell culture and transfections
COS-7 cells were grown and transfected as previously
described [46] using Lipofectamine Plus reagent (Invitro-
gen) at 20 μg/ml. Cells were transiently transfected with 1
μg of each of the five pGEM constructs, pcDNA3CAT, or
pKCAT (a promoterless pcDNA3CAT), and co-transfected
with pSVβ-gal (Promega, Madison, WI) to allow normali-
zation of transfection efficiency. After 4 hr, fetal bovine
serum was added to a final concentration of 10%. Cells
were harvested after 48 hr.
CAT and β-galactosidase assays
Two methods were used to measure CAT reporter protein
expression, a radioactive enzyme activity assay and an
enzyme-linked immunosorbant assay (ELISA) for protein
quantification. Protein extracts, prepared per manufac-
turer's protocol in Reporter Lysis Buffer (Promega), were
used for the CAT activity assay and the β-galactosidase
ELISA assay (Promega). For the radioactive CAT enzyme
assay, cell lysates were prepared with chloramphenicol
(50 μM final concentration) and 14C-butyryl-Coenzyme A
(8.3 μCi/mmol final concentration) (Moravek Biochemi-
cals, Brea, CA) and added to 4 ml Econofluor II scintilla-
tion fluid (PerkinElmer, Wellesley, MA) (5 ml total
volume) as described by Neumann et al [47]. The radioac-
tivity transferred to chloramphenicol by CAT was counted
for 0.5 min/tube, and counts were repeated at 45 min
intervals during the assay period until counts plateaued.
Commercial CAT enzyme (Promega) served as a positive
control. CAT activity, as determined by subtracting the
activity of mock transfected samples (no DNA added),
was normalized to β-galactosidase activity. CAT and β-
galactosidase proteins were quantified using ELISA assays
(Roche Applied Science, Indianapolis, IN) according to
the manufacturer's instructions. CAT protein was normal-
ized to β-galactosidase protein. Both methods for evaluat-
ing reporter protein expression were performed in
duplicate and repeated a minimum of three times. The
Student's T-test was used to analyze CAT activity levels
between the pGEM-GGG -44 G construct and the other 5'
UTR -44 C containing constructs. The Wilcoxon Rank-
Sum test was used to analyze the CAT protein concentra-
tions due to non-normal data distribution.
RNA extraction and real time quantitative PCR (QPCR)
Total RNA was extracted from HOK cells using the RNeasy
Mini Kit (Qiagen, Valencia, CA). Reverse transcription was
performed with 500 ng HOK RNA using the RETROscript
Table 1: Oligonucleotide PCR primers utilized
Name Sequence Anneal. Temp.
DNA Sequencing
HBD1 SEQ AACTCTAGCAGGTACCAGAGCTTACCT 65
CTAACCTAGAAAACCAAACAGGAGGAG
DEFB1 SNEST TGAGGCCATCTCAGACAAAA 65
GCTCCAGGCGTAAAGCTAAA
QPCR Primer Efficiency
HBD1 CACTTGGCCTTCCCTCTGTA 1.91 56
CGCCATGAGAACTTCCTACC
HBD2 GGAGCCCTTTCTGAATCCGCA 1.98 65
CCAGCCATCAGCCATGAGGGT
HBD3 GTGAAGCCTAGCAGCTATGAGGAT 1.68 60
TGATTCCTCCATGACCTGGAA
RPO GCCTTGACCTTTTCAGCAAG 2.04 59
GCAGCATCTACAACCCTGAAG
Beta-actin CTCTTCCAGCCTTCCTTCCT 1.75 63
AGCACTGTGTTGGCGTACAGBMC Oral Health 2009, 9:21 http://www.biomedcentral.com/1472-6831/9/21
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kit (Ambion, Austin, TX) with oligo(dT) primers accord-
ing to the manufacturer's protocol. The reaction mix con-
tained 250 nM oligo(dT)primer, 10 mM deoxynucleoside
triphosphate mix, 50 U of reverse transcriptase and 13 U
of RNase inhibitor, and buffer. QPCR amplification of the
resulting cDNA was carried out for hBD1, hBD2, hBD3,
beta-actin, and the housekeeping gene ribophosphopro-
tein, RPO. Table 1 lists primers used. QPCR was per-
formed in a MyiQ iCycler (Bio-Rad, Hercules, CA) using
the iQ SYBR® Green Super Mix (Bio-Rad). Melt curve anal-
ysis confirmed that the signal was generated by the
expected amplification product. The threshold cycles for
detection level of hBD1, hBD2, hBD3, and beta-actin were
normalized to the housekeeping gene RPO and compared
among cell lines with three genotypes of the -44 SNP (CC,
CG, and GG). The relative fold change was calculated by
the Pfaffl method [48]. Because this method requires a
standard for comparison, we used a reference consisting
of mRNA pooled from 4 HOK donors randomly selected
and combined as a baseline for the entire study. Results
are expressed as the relative fold change for each mRNA
from individual genotypes compared to this combined
RNA reference baseline. Messenger RNA expression data
were log-transformed due to non-normal data distribu-
tion.
Antimicrobial assays
Epithelial cell protein extracts for ELISA and microbial
assays were prepared from triplicate post-confluent cell
cultures grown in 24-well plates. Cultures were washed
with PBS and extracted with ice cold extraction buffer (50
mM Tris, pH 7.4, 5 mM EGTA, 150 mM NaCl, 1% Triton
X-100 containing protease inhibitors (1 mini-protease
inhibitor tablet (Roche Applied Science) per 7 ml buffer)
using a total of 100 μl and stored in aliquots. Total HOK
protein was measured using the BCA assay (Pierce Bio-
technology, Inc. Rockford, IL).
hBD-3 peptide in HOK extracts was assayed by ELISA
(PeproTech, Rocky Hill, NJ) using rabbit anti-hBD-3
according to manufacturer's procedure. Protein extracts
were diluted 1/20 and standard hBD-3 peptide (Pepro-
Tech) was diluted so that the buffer concentration was
equivalent in sample and standard peptide dilutions.
Radial diffusion assay for inhibition of bacterial growth
was as modified from the procedure described by Lehrer
and coworkers [49]. Briefly, Gram positive Staphylococcus
epidermidis UW3 [50] was grown to mid-log phase and
centrifuged, washed, and resuspended in 10 mM phos-
phate buffer, pH 7.4. Bacteria (4 × 106) were added to 10
ml 1% LMP agarose (Invitrogen) containing 1% Todd
Hewitt broth, 10 mM phosphate buffer, pH 7.4 and
poured into a square Petri dish. Three mm wells were
punched and 4 μl control peptide or HOK protein extract
containing 4 μg protein added per well. Plates were incu-
bated for 3 hr at 37°C to allow sample to be absorbed into
the agarose, then ten ml nutrient overlay agarose (1% aga-
rose with 200% Todd Hewitt broth) was added and the
plates incubated at 37°C overnight. Plates were fixed with
10 ml 5% acetic acid/25% methanol solution, digitized
images were obtained using a CCD camera (Alpha
Innotech, San Leandro, CA), and the circle of clearing
measured using NIH ImageJ 1.38 u software http://
rsb.info.nih.gov/ij/. Measurements were done in a
blinded fashion. Triplicate HOK protein extracts were
tested in duplicate. Results were analyzed by comparing
the area of the zone of clearing minus the area of the well
for each sample.
Statistical analysis
Differences in mRNA expression and antimicrobial activ-
ity by radial diffusion assay among the three -44 SNP gen-
otype groups were analyzed one-way analysis of variance
(ANOVA). Further testing was performed on individual
groups by the Dunnett T3 method [51] which does not
assume equal variances. For all comparisons p ≤ 0.05 was
considered statistically significant.
Results
The -44 SNP affects the predicted structure of the DEFB1 
5' UTR
The DEFB1 5' UTR contains the -44 SNP site (rs1800972)
as well as two additional SNPs (-20, rs11362 and -52,
rs1799946). To see if these SNPs have an effect on the
mRNA secondary structure the predicted folding pattern
and Gibbs free energy were computed by MFOLD [44] for
hBD1 mRNA with common sequence variants or haplo-
types (Figure 1). The putative secondary structure for the
DEFB1 5' UTR containing the two most common haplo-
types, GCA (-52,-44,-20)(Figure 1) and ACG (not shown),
show the -44 site on exposed loops, but this site is buried
in the naturally occurring GGG haplotype which has the -
44 G allele (Figure 1). The site is also on an exposed loop
in the GCG haplotype (not shown), which was designed
as a direct control for the GGG haplotype sequence, but
was not observed in the populations analyzed in our lab-
oratory. These putative structural characteristics led us to
test the DEFB1  5' UTR for effects on reporter protein
expression in a model system
The -44 SNP G allele results in increased reporter protein 
expression in vitro
The effect of the DEFB1 -44 G allele on gene expression
was evaluated in COS-7 cells using constructs containing
different haplotypes of the DEFB1 5' UTR fused to the CAT
reporter gene (Figure 2A). Two different assays showed
greater CAT expression for the pGEM-GGG construct car-
rying the -44 G allele. CAT enzyme activity was 1.7 fold (p
< 0.01) greater with pGEM-GGG CAT than that observedBMC Oral Health 2009, 9:21 http://www.biomedcentral.com/1472-6831/9/21
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with pGEM-GCA and pGEM-GCG. It was also greater (1.5
fold, p = 0.01) than the pGEM-ACG construct (Figure 2B).
Similarly, CAT protein expression as measured by ELISA
showed that pGEM-GGG had the highest expression in
COS-7 cells compared to pGEM-GCA (2.8 fold greater, p
= 0.001), pGEM-GCG (1.6 fold greater, p = 0.036) and
pGEM-ACG (1.5 fold greater, p = 0.047) (Figure 2C).
Hence, by both assays, CAT protein expression is signifi-
cantly increased in cells expressing the -44 G allele in the
context of the naturally observed 5' UTR haplotype, GGG,
compared to the two most common haplotypes with the -
44 C allele, ACG and GCA. Reporter protein expression in
cells transfected with the GGG haplotype was also signifi-
cantly higher than the GCG construct, the direct 5' UTR
control, demonstrating that the -44 G allele alone influ-
ences reporter gene expression.
Genotyping of primary human keratinocytes and 
association of the -44 SNP with hBD1 mRNA expression
To examine the effect of the DEFB1 -44 SNP in the context
of the whole gene, human keratinocytes (HOK) from
twenty-four independent donors were evaluated for the
DEFB1  exon 1 sequence. Sixteen cell lines were
homozygous at the -44 site for the common allele, C; six
were heterozygous at this site; and two were homozygous
for the -44 G allele (Figure 3). The allele frequency
observed for the -44 G allele (0.21) is close to that previ-
ously reported [30,31]. Frequency of the GG genotype in
the population is predicted to be 4% based on Hardy
Weinberg equilibrium, thus we were fortunate to identify
the GG genotype in two donors. All HOKs with one or
more copies with the -44 G allele had a genotype consist-
ent with the GGG haplotype for the -52, -44, -20 SNPs in
accordance with our previous report [31].
Twelve of the HOK donor lines representing the three -44
genotypes, 5 CC, 5 CG and 2 GG, were further evaluated
Putative secondary structure for the 5' UTR of DEFB1 mRNA Figure 1
Putative secondary structure for the 5' UTR of DEFB1 mRNA. Two of the four haplotypes (-52, -44, -20 SNP sites) 
used in the CAT constructs as calculated and drawn by the MFOLD Quikfold program. The locations of the SNP sites are 
boxed and the -44 SNP sites are shown in red boxes. Note that the -44 SNP site in the GGG haplotype is in a hybridized stem 
structure. In contrast, as represented by the GCA structure shown, the -44 SNP site is in a loop or non-hybridized configura-
tion in the other three haplotypes. Similar putative structures were obtained in three separate trials. Secondary structures with 
the lowest ΔG (G = Gibbs free energy) were evaluated. The ΔG values are: GCA = -13.5, GCG = -12.8, ACG = -10.5, GGG = 
-13.9.
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for mRNA and antimicrobial activity. Given the small
sample size available and low power to show differences
between groups, the statistical tests were not expected to
give definitive results. Nevertheless, because each donor
cell line was analyzed in triplicate and some differences
were large, we were able to demonstrate statistically signif-
icant differences among the groups for several variables.
HBD1 mRNA expression was significantly greater in those
cells with the GG genotype compared to the homozygous
common allele C in HOKs cultured in both 0.15 mM (p =
0.021) and 0.6 mM calcium (p = 0.023) and to the heter-
ozygous CG genotype (p = 0.024; p = 0.003 in 0.15 mM
and 0.6 mM calcium) (Figure 4A). Thus, although our
sample of the GG genotype is small, cells with this geno-
type have significantly greater constitutive hBD1 mRNA
expression. In contrast, beta-actin mRNA levels were not
correlated with genotype (not shown).
Effects of the -44 SNP on the constitutive level of hBD2 
and hBD3
The level of hBD2 and hBD3 mRNAs were determined to
identify possible effects of the DEFB1 -44 SNP on other β-
defensin genes in the chromosome 8p defensin cluster.
Because the cultures were not exposed to cytokines or bac-
terial products, these values represent the constitutive
level of the mRNAs. HBD2 mRNA expression was not sig-
nificantly correlated with the DEFB1 -44 SNP in either
growth condition (p = 0.570, p = 0.577) (not shown). Sur-
prisingly, we found a significant correlation with the
DEFB1 -44 SNP and expression of hBD3 mRNA in both
growth conditions (Figure 4B). The expression of hBD3
increased with the -44 G allele (CC<CG<GG). HOKs with
the GG genotype grown in 0.15 mM calcium had a mean
level of hBD3 mRNA 18-fold greater than those with the
CC genotype (p = 0.011). In 0.6 mM calcium HOKs with
the GG genotype had 16-fold greater relative expression of
hBD3 than those with the CC genotype (p = 0.002). In
both growth conditions hBD3 mRNA expression in the
GG homozygous group was also significantly different
from the heterozygous CG genotype group. These results
suggest that the -44 G allele in DEFB1 is associated with
increased hBD3 mRNA expression.
We also evaluated the effect of the DEFB1 -44 SNP on
hBD3 peptide expression by ELISA (effective reagents
were not available for hBD1 and hBD2). HOKs with the
GG genotype had a median level of hBD3 peptide two-
fold greater than those with the CC genotype (ANOVA p
= 0.014), but this was not statistically significant in further
analysis accounting for unequal variances between groups
due to the small sample size (not shown).
Antimicrobial activity is increased in HOKs with the -44 G 
allele
A radial diffusion assay was used to test for overall antimi-
crobial activity of HOK extracts using Staphylococcus epider-
midis UW3, a Gram positive commensal skin organism
which has been previously demonstrated to be susceptible
Effect of the 5' UTR haplotype on reporter protein expression Figure 2
Effect of the 5' UTR haplotype on reporter protein expression. A. Schematic representation of reporter gene con-
structs; details of construction provided in Methods and Additional file 1. Arrows indicate SNP sites in hBD1 5' UTR. Bent 
arrows indicate direction of translation. Light grey bars represent 5' UTR. Construct names are given at left, the SNP haplo-
types comprise the latter portion of the name. B. and C. CAT expression in COS-7 cells transiently transfected with con-
structs containing hBD1 (or CMV) 5' UTR. CAT expression is normalized to β-galactosidase. (B) CAT activity measured by 
radioactive enzyme activity assay. Mock transfected (no DNA added) CAT values were subtracted and CAT activity was nor-
malized to β-galactosidase activity obtained by ELISA enzyme activity assay. (C) The quantity of CAT protein was measured by 
an antibody-based ELISA and normalized to β-galactosidase protein. Black bars in B and C represent constructs containing 
hBD1 5' UTR with the -44 G allele. Values given are averages and standard errors from 3 or more experiments. Statistically sig-
nificant differences are indicated with asterisks compared to pGEM-GGG. *, p < 0.05; ** p < 0.01; *** p < 0.001.
A BCBMC Oral Health 2009, 9:21 http://www.biomedcentral.com/1472-6831/9/21
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to hBD1 (our unpublished findings) as well as hBD3 [52].
The mean area of clearing increased with the -44 G allele
(CC<CG<GG) and extracts from cells with the GG geno-
type showed significantly greater zones of clearing than
those with the CC genotype (p = 0.04) (Figure 5).
Interferon-γ induced levels of hBD1 and hBD3 mRNA are 
correlated with genotype
Induced levels of hBD1, hBD2, and hBD3 were evaluated
in HOKs from the twelve donors (5 CC, 5 CG, 2 GG) in
the presence of LPS and PAM3CSK4, ligands for TLR4 and
TLR2, respectively, as well as, IL1β, TNFα, and IFNγ.
HBD1, hBD2 and hBD3 mRNA were not upregulated by
LPS or PAM3CSK4, as anticipated. TNFα and IL1β
induced hBD2 in highly variable amounts in different cell
donors, not correlated with genotype, but had little effect
of hBD1 and hBD3 mRNA (not shown). In contrast, IFNγ
stimulation resulted in significant upregulation of both
hBD1 (p = 0.02) and hBD3 mRNA (p = 0.005) that was
correlated with genotype with the common -44 CC geno-
type averaging 12-fold and 100-fold increase over unin-
duced levels, respectively (Figure 6).
Discussion
Antimicrobial peptides play an important role as part of
mucosal and skin innate immunity. Therefore, genetic
variation that results in altered peptide expression may
influence susceptibility to infection. Here, we demon-
strate that the DEFB1  -44 G allele is associated with
increased constitutive expression of both hBD1 and hBD3
Genotypes at DEFB1 5'UTR SNP sites from 24 keratinocyte  donors Figure 3
Genotypes at DEFB1 5'UTR SNP sites from 24 kerati-
nocyte donors. Those samples that were used for further 
studies are indicated by *.
  SNP Site  
 -52  -44  -20 
Donor  G/A C/G G/A 
  13*           
  17*  
  18  
  20*  
  31  
  33  
  35  
  37  
  41  
  42  
  14*  
  21*  
  11  
  27  
  36  
  40  
  34 * 
  38*  
  10*  
  16*  
  22*  
  39  
  26*  
  29*  
  
  
Common allele
Rare allele
Heterozygote
Association of constitutive antimicrobial gene expression  with the DEFB1 -44 SNP genotype Figure 4
Association of constitutive antimicrobial gene 
expression with the DEFB1 -44 SNP genotype. cDNA 
was made from primary keratinocytes from 12 donors 
grown in 0.15 mM Ca2+ (left) or 0.6 mM Ca2+ (right). QPCR 
amplification of cDNA for hBD1(A) and hBD3 (B) and the 
housekeeping gene RPO was performed. All data were nor-
malized to the housekeeping gene and compared to a sepa-
rate reference cDNA. The data presented are log2 
transformed and represent 3 replicates for each cell line with 
duplicate QPCR reactions. The mean and std. dev. for each 
group is shown. *, p < 0.05; ** p < 0.01.
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mRNA, with increased antimicrobial activity in oral kerat-
inocytes, and with increased reporter protein expression
in transfected cells, suggesting that the GG genotype
results in enhanced transcription of the DEFB1 gene or
with enhanced post-transcriptional events. We also dem-
onstrate the first evidence of a significant relationship
between the -44 SNP in the DEFB1 gene with expression
of DEFB103 gene encoding hBD3 in the nearby gene clus-
ter. The antimicrobial functional assay also supports
greater peptide expression in keratinocyte extracts. This
assay is not specific for hBD1 but could be the result of
increased expression of other defensins including an
increased level of hBD3 peptide. Results from our model
system as well as the keratinocyte expression data demon-
strate that the DEFB1 SNP -44 G allele is associated with
increased constitutive antimicrobial peptide expression
and function. Thus, within the context of the β-defensin
genes, the -44 SNP is associated with a direct cis effect on
the expression of hBD1 and an indirect effect on hBD3
expression. Together, these findings suggest a mechanism
which supports genetic studies that have demonstrated a
correlation between the DEFB1 5' UTR -44 SNP G allele
and protection from various types of infection [34-36,39].
The approach of examining transcript and reporter pro-
tein expression in a model system is designed to investi-
gate direct cis effects of the DEFB1 UTR. Using an in vitro
system in which we tested the expression of different
DEFB1 5' UTRs fused to the CAT reporter gene, we have
shown that the -44 G allele is specifically associated with
increased protein expression. While our studies agree with
previous findings of a 2.3 fold increase of luciferase
expression with the -44 G allele compared to the more
common C allele in a short promoter construct [33], Mila-
nese and coworkers [53] reported a 53% decrease in tran-
scription with the -44 G construct. These differences may
be related to a possible role of the SNP in post-transcrip-
tional regulation or mRNA stability that varies with cell
type. The difference in predicted mRNA structure for the
DEFB1 5' UTR between the -44 genotypes, the highly con-
served nature of the DEFB1 5' UTR in primates [54] and
the length of this region (71 nucleotides), considerably
longer than that of DEFB4 (36 nucleotides) and DEFB103
(30 nucleotides), are consistent with a possible role for
the 5' UTR in post-transcriptional control via RNA-bind-
ing domains [55].
In physiological conditions, the level of β-defensin
expression in many tissues varies with exposure to bacte-
ria and proinflammatory cytokines. Thus it was of interest
to examine induced levels of these antimicrobial peptides.
A significant correlation of hBD1 and hBD3 mRNA with
genotype was not seen for proinflammatory cytokines
IL1β and TNFα, and although hBD2 was highly upregu-
lated by these stimulants, expression was not associated
Association of the DEFB1 -44 SNP genotype with increased  constitutive antimicrobial activity Figure 5
Association of the DEFB1 -44 SNP genotype with 
increased constitutive antimicrobial activity. Total cell 
lysates prepared from cultured keratinocytes (4 μg protein) 
were added to solidified agarose containing S. epidermidis. 
The area of clearing in square mm. minus the area of the well 
was calculated and results compared by genotype. The data 
represent 3 replicates from each cell line and the assay was 
performed in duplicate. The data are log transformed and the 
mean and std. dev. are shown.
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Association of the DEFB1 -44 SNP genotype with hBD1 and  hBD3 mRNA expression in HOKs induced with IFNγ Figure 6
Association of the DEFB1 -44 SNP genotype with 
hBD1 and hBD3 mRNA expression in HOKs induced 
with IFNγ. QPCR was conducted as in Figure 4. Log trans-
formed mean and std. dev. are shown. Note increased hBD1 
and hBD3 mRNA in the CC genotype. The data represent 2–
3 replicates from each cell line with duplicate PCR assays.
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with the -44 DEFB1 SNP genotype. HOK expression of
these three β-defensins was not induced by TLR2 and
TLR4 ligands, in agreement with previous results for this
cell type which is hyporesponsive to purified ligands, but
responds to more complex bacterial signals [11,12,56]. In
contrast to constitutive levels, HOKs with the more com-
mon CC genotype had increased mRNA levels for hBD1
and hBD3 in the presence of IFNγ. Induction of hBD1 and
hBD3 by IFNγ was anticipated [57,58], but the association
of hBD3 upregulation with DEFB1  SNP genotype was
quite unexpected. This result suggests the possibility of
linkage disequilibrium of the DEFB1  -44 SNP and a
DEFB103 promoter site.
Genetic variation that affects level of expression is gener-
ally associated with transcription factor binding sites in
the promoter region of genes, however, the DEFB4 and
DEFB103 genes, encoding hBD2 and hBD3, respectively,
also exhibit copy number polymorphism [26,59] which
affects expression levels. Copy number polymorphisms
are frequently in linkage disequilibrium with SNPs in
nearby genes [60]. Linkage disequilibrium of the -44 SNP
G allele of DEFB1  w i t h  a  h i g h  c o p y  n u m b e r  o f  t h e
DEFB103 gene may be the explanation for the increased
constitutive expression hBD3, while the DEFB1  -44 C
allele may be associated with a DEFB103 promoter region
alteration that affects IFNγ inducibility. Investigation of
these possibilities is beyond the scope of the present work,
nevertheless, it seems clear that a high constitutive level of
hBD1 and hBD3 expression may be beneficial in some sit-
uations while the greater IFNγ inducibility may be benefi-
cial in others.
Our findings have biological relevance in understanding
mechanisms that may be associated with a disease suscep-
tibility risk that correlates with the -44 SNP G allele. Sev-
eral factors contribute to a protective function including
direct effects resulting in increased constitutive hBD1 and
hBD3 antimicrobial activity and increased immunomod-
ulatory effects of these defensins. Higher constitutive level
of hBD1 and hBD3 in individuals with the -44 G allele is
consistent with the protection from oral Candida carriage
[34] and may be biologically important to enhance resist-
ance of the epithelium to Candida colonization because
hBD3 has strong anti-candidal activity [57,61,62]. Simi-
larly, the protection from chronic obstructive pulmonary
disease [35] and lower risk of HIV-1 infection in children
born to HIV-1 positive mothers (Braida, 2004) associated
with the -44 G allele may be related to increased expres-
sion of hBD3 which has more potent direct antimicrobial
activity than hBD1 with has direct anti-viral properties by
blocking viral replication [63] and acting as an antagonist
of the HIV-1 co-receptor, CXCR4 [64].
On the other hand, the more common C allele of the
DEFB1 -44 SNP results in greater levels of hBD1 and hBD3
in the presence of IFNγ. Therefore, in pathological condi-
tions in which T helper cell type 1 immune response is
elicited, the CC genotype may be protective. This includes
periodontitis which has been considered a Th1 type con-
dition [65-67] with elevated levels of IFNγ in gingival
fluid of active periodontal lesions [68,69]. Periodontal
pathogens like P. gingivalis and Aggregatibacter actinomyce-
temcomitans induce the secretion of IFNγ from leukocytes
and T-cells, respectively [70,71]. Thus, IFNγ not only
exhibits pro-inflammatory characteristics during progres-
sion of active periodontal lesions, but may also promote
protective capabilities in the early stage of infection by
increasing the gene expression of hBD1 and hBD3 in
HOKs carrying the common -44 CC genotype. Because
hBD1 and hBD3 are highly expressed in the -44 GG gen-
otype, it may be that induction by IFNγ remains unappar-
ent for this genotype, whereas the common -44 CC
genotype with low baseline expression of hBD1 and hBD3
could allow at least a short term protective effect by IFNγ.
Therefore, perhaps it is not surprising that the -44 SNP has
not been associated with either early onset [72] or with
severe chronic periodontal disease [73].
Conclusion
The G allele of the -44 DEFB1  SNP is associated with
higher constitutive levels of both hBD1 and hBD3 in
keratinocytes in a manner that is consistent with protec-
tion from oral candidiasis. In contrast, the more common
C allele is associated with greater hBD1 and hBD3 expres-
sion in IFNγ-stimulated keratinocytes and is likely to be
protective in conditions with elevated IFNγ such as
chronic periodontitis. The contrast of constitutive vs.
induced levels of hBD1 and hBD3 will make interpreta-
tion of genetic studies for the DEFB1  -44 SNP locus
extremely complex.
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